logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Triple-negative breast cancer: neoadjuvant/adjuvant pembrolizumab improves pathological complete response

First phase 3 trial of pembrolizumab in early TNBC shows promise.